New tool to rule out coronary heart disease in primary care

Jul 05, 2010

A simple new rule can help primary care physicians rule out coronary heart disease in patients with chest pain, states a study published in CMAJ (Canadian Medical Association Journal).

Chest pain is common, yet it is challenging for primary care physicians to reliably identify serious cardiac disease while protecting patients from unnecessary interventions.

The authors developed a clinical decision rule called the Primary Care CHD Score ("Marburg Heart Score") with five predictors that can be easily identified during a patient's visit: age/gender, known clinical vascular disease, pain worse with exercise, patient assumes cardiac origin of pain and pain not reproduced with palpitation.

"The aim of our study was to develop a simple, valid, and usable prediction score based on signs and symptoms to help physicians rule out coronary heart disease (CHD) in patients presenting in ," write Dr. Stefan Bösner, University of Marburg, Marburg, Germany and coauthors.

In a related commentary, Richard Stevens and Daniel Lasserson of University of Oxford, UK, write "the challenge is correctly identifying and referring the patient with while minimizing the number of referrals of patients who do not have CHD, to reduce the harm of unnecessary investigation and burden on healthcare resources." The authors suggest this decision rule shows promise for improving the diagnosis of CHD.

Explore further: New drug sales help boost Novartis Q1 profit (Update)

More information: www.cmaj.ca/cgi/doi/10.1503/cmaj.100212

add to favorites email to friend print save as pdf

Related Stories

What is the etiology of cardiac syndrome X?

Dec 01, 2008

Non-cardiac chest pain remains a widespread symptom especially in western countries with a significant economic burden. Patients with chest pain and abnormal electrocardiographic (ECG) but normal coronary angiogram (i.e. ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.

Ocean microbes display remarkable genetic diversity

The smallest, most abundant marine microbe, Prochlorococcus, is a photosynthetic bacteria species essential to the marine ecosystem. An estimated billion billion billion of the single-cell creatures live i ...